Method of producing substituted quinazolinons-2

专利摘要:
The synthesis of substituted quinazolinones is described. The novel quinazolinones are renal vasodilators and thereby increase renal blood flow, and are useful as cardiovascular agents.
公开号:SU1344246A3
申请号:SU853856863
申请日:1985-02-15
公开日:1987-10-07
发明作者:Т.Бандурко Виктор；Дж.Тобиа Альфонсо；Д.Левин Сеймур；М.Малвей Дейнис
申请人:Орто Фармасьютикал Корпорейшн (Фирма)；
IPC主号:

专利说明:

The invention of pitsit to a method for producing new substituted quinazolium-2 ions of the general formula
where R is lower alkyl,
who have cardiotonic activity and may find medical contact.
The purpose of the invention is to obtain new substituted quinazolinones, which are intermediate to obtain compounds with renal vasodilating activity and exhibiting higher cardiotonic activity compared with the structural analogue.
Example 1. Preparation of the starting compound 2,3-dimethoxy-6-nitrobenzaldehyde.
To a suspension of NaH (16.0 g, 50% dispersion in oil, 33 / mmol in dimethylformamide (DMF) (200 ml) is added dropwise a solution of 2-hydroxy-3-methoxy-6-nitrobenzaldehyde (49 , 0 g, 248 mmol) in DMF (300 ml) at such a rate that the temperature does not exceed 35 ° C. The mixture is kept at room temperature for 1 hour, then a large excess of iodide methyl (100 ml A) After a weak exothermic reaction, the mixture is vigorously stirred for 19 hours at room temperature, after the removal of methyl iodide, the reaction mixture is poured into ice-cold water (1 l). The brown solid is filtered off, washed with water (cold) and then recrystallized from isopropyl alcohol (700 ml). The product is obtained as a tan solid, 27.9 g (53.3%), m.p. Yub-Yub S.
About p and m e r 2. Obtaining the target product of 5,6-dimethoxy-4-methyl-2- - (1H) -quinazolinone.
Step 1. 2, 3-Dimethoxy-6-nitro-benzaldehyde ethylenketketal.
A mixture of 2, 3-dimethoxy-6-nitrobenzaldehyde (16.0, i-, 75 mmol), ethylene glycol (64 g, 103 mmol) and p-toluenesulfonic acid mogogidrat (O, 2 g
in benzene (750 ml), heated at reflux temperature in a Dean-Stark apparatus for 48 hours. The solution is poured into ice water (1 l). The organic phase is washed with saturated aqueous NaHCG solution (2x20 ml), dried over Na2S04, filtered the solvent is removed in vacuo.
The crude product is recrystallized from n-hexane (2l), yield 15.2 g (78.2%), so pl. 74-76 0.
Step 2. 2,3-Dimethoxy-6-amino-benzaldehyde ethylene ketal.
A solution of 2,3-dimethoxy-6-nitrobenzaldehydeethylene ketal (12.1 g,
62.7 mmol) in ethyl acetate (350 ml) containing sodium acetate (0.5 g), treated with platinum oxide (1.0 g)
and the mixture is hydrogenated for
24 hours at a pressure of about 50 pounds per KB inch. The catalyst is filtered off and the solvent is removed in vacuo. Get light brown
butter. After crystallization from n-hexane, the product is obtained as a tan solid, 12.8 g (85.1%) of injection, mp 78-80 ° C.
Stage 3. 2,3-Dimethoxy-6-ethoxycarbonylaminobenzalde hydroethylene-. tal.
Ethyl chloroformate (1.9 g, 17.5 mmol) was added with stirring to 6-amino-2 5 3-dimethoxybenzaldehydeethyl ketal (1.6 g, 7.1 mmol) dissolved in tetrahydrofuran (50 ml) and added sodium hydroxide in water (0.72 g in 3.5 ml) and the resulting solution is stirred for 2 hours at room temperature. The tetrahydrofuran is removed in vacuo and the residue is extracted with CHClCl (2x X 100 ml). The extracts are dried over)
filtered off and the solvent was removed in vacuo. The crude product was crystallized from n-hexane, 1.2 g (57.1%) was added, m.p. 95-96 ° C.
Step 4. 2, 3-Dimethoxy-6-ethoxycarbonylaminobenzaldehyde.
2, 3-Dimethoxy-6-ethoxycarbonyl-aminobenzaldehyde ethylene ketal (5.0 g,
16.8 mmol) dissolved in a mixture of acetone (36 ml) and aqueous solution of HC1
(3 ml, 1N. Solution). The mixture was stirred at room temperature for 4 hours. The solvent was removed in vacuo to give a yellow solid (3.9 g). After recrystallization
the n-hexane was obtained from the pure product as a yellow solid, yield 3.6 g (84.7%), mp. 86-.
Step 5. 5,6-Dimethoxy-2 (1H) -chi-nazolinone.
A stream of dry gaseous ammonia is passed through a solution of 2,3-diovolumes of about 250 ml of a mild-white precipitate, which is filtered off, crystallized from isopropanol (200 ml) and the product is obtained as a colorless solid, yield 9.7 g (87, 8%), mp. 210-212 ° C.
Step 7. 5,6-Dimethoxy-4-methylmethoxy-6-ethoxycarbonylaminobenzal -2 (1H) -quinazolinone.
of dehydrate (12.4 g, 48.9 mmol) in ammonium acetate (95 g), the temperature of which is maintained at a level of 155 - for 3 hours. The reaction mixture
Potassium permanganate (25.6 g, 162.38 mmol) was added to a solution of 3,4-di-hydro-5,6-dimethoxy-4-methyl-2 (1H) -quinazolinone (18.04 g, 81, 19 mmol)
cooled and poured into a mixture of 15 in acetone (5.0 l) and the mixture is stirred with ice. A brownish yellow solid is formed. The aqueous mixture is treated with NaCl (50 g) and then extracted with CHCl.j (3 x 200 mlX. The extracts are combined, the solvent is removed in vacuo and 9.2 g of a pale brown oil are obtained. After triturating this oil with acetone (mountains part) receive the product as a yellow solid, yield 2.1 g (20.8%), so pl. 242-244 C.
Stage 6. 3,4-Dihydro-5,6-dimetok c-4-methyl-2 (1H) -quinazolinone.
To a suspension of 5,6-dimethoxy-2 (1H) - -quinazolinone (10.0 g, 48.5 mmol) in anhydrous tetrahydrofuran (1100 ml under nitrogen atmosphere, an excess amount of methyl bromide in diethyl ether (62, 60 ml, 3.1 M solution in diethyl ether, 194.06 mmol). Then the reaction mixture is removed from the cooling bath, allowed to warm to room temperature and stirred at room temperature for 16 hours. Add additional amount of methyl bromide (15 , 65 ml, 3.1 M solution in diethyl ether, 48.52 mmol) and the reaction mixture is heated at t reflux distilled for 2 hours. Cool in an ice bath and add an aqueous solution of W 4 C 1 (100 ml of saturated NH 4 C 1 in 100 ml of HjO) with stirring. After this, add 10% aqueous hydrochloric acid until the pH reaches L 6, 0. The layers are separated and the aqueous layer is extracted with CHCl1 (3x250 ml). The extracts are combined with the previously separated tetrahydrofuran layer, a volume-gg tracheal tube with a cuff, using a Harvard respirator. In the femoral zone, a full water {NaCl artery and vein solution was placed in polyethylene (200 ml) and dried over Na2S04. After new catheters to record medium filtration and concentration to arterial blood pressure
a volume of about 250 ml gives a white-white precipitate, which is filtered, crystallized from isopropanol (200 ml) and the product is obtained as a colorless solid, yield 9.7 g (87.8%), mp. 210-212 ° C.
Step 7. 5,6-Dimethoxy-4-methyl potassium permanganate (25.6 g, 162.38 mmol) was added to a solution of 3,4-di-hydro-5,6-dimethoxy-4-methyl-2 (1H) - -quinazolinone (18.04 g, 81.19 mmol)
The resulting brown precipitate is filtered off, washed with acetone (500 ml) and partially dissolved in boiling water (1000 ml). The aqueous solution (after filtering ) neutralized with a 10% aqueous solution of hydrochloric acid and then extracted with CHCl2 (4x250 ml) and a mixture of 10% isopropyl alcohol with ethyl acetate (4x250 ml). The resulting extracts are dried over MgSO4, filtered and concentrated to 500 ml, a solid is formed which e is filtered off. The filtrate is again concentrated in vacuo to give 3.25 g of a tan solid, which is chromium 5
0
five
0
Computed on silica gel prepared in CHCl 4 (500 ml fraction). After elution with 0.5% methanol / chloroform, a yellow solid is obtained (1.92 g), from which, after recrystallization from isopropanol (75 ml), the desired product is obtained as yellow solid, yield 0.940 g (5.3%), so pl. 230- 232 C.
Cardiotonic studies.
Preparation of an anesthetized dog with an open chest.
Muddy dogs of any sex (8–20 kg) were anesthetized with sodium pentobarbital (Nembutal), 45 mg / kg administered intraperitoneally, and artificial respiration with room air through endo (MAP) and drug delivery. Pressure sensor with a catheter at the end Type Milar PC 370 was inserted into the left ventricle through the left carotid artery to measure pressure in the left ventricle (LVP). Pressure pulses were used to trigger a Beckman cardiotachometer to determine the frequency of heartbeats (HP) and the shape of pressure signals in the left ventricle were differentiated using a Beckman type 8758 communication device to obtain LV dP / dt max (dP / dt) index myocardial contractility. The rights of tarokotomi were performed in the fourth intercostal space
and the bag was open around the heart. A Walton Brodie external calibration arc was sewn to the free wall of the right ventricle and lengthened by approximately 30% of its closed position to measure changes in contraction force (SG). The reaction was continuously observed on Beckman’s P612 dynograph of 2800 firm. Bould.
In tab. Figure 1 illustrates the comparative data on the intravenous efficacy and activity of ORF 16600 and its dimethoxyaromatic positional isomers.
Table 1
ORF-16600 CHjO CHjO
4558
16046 16340 16421 16317 16280
CH ,, 0 CHgO
H H CH ,, 0 H
H CHgO
CHjO H
HO
HO
CHgO
SNZO
H H H
CHgO
CHjO
SNZO
H H H
CH, 0
CH.jO
Connection Activity,% of control
+88
+ 100
+ 114
+90
+95
+54
+93
+60
+54
+39
The data table. 1 show that the efficiency of OPF 16600 is about 10 times greater than that of any analog. The transition from 5.6 to 6.7 and 7.8 dimethoxy isomers leads to both a loss of efficacy and a positive inotropic activity. Dioxy-oxidized ORF 16600 (for example, 16280) has marginal activity. These data clearly show the difference between ORF 16600 and its positional isomers.
The magnitude LCjg indicates the relative ability of a compound to inhibit an enzyme. The lower the value, the more efficient the connection.
In tab. 2 compares the relative efficiencies of ORF 16600 and ORF 14558 using data on contraction strength, experimentally determined dose-response. If the ORF 16600 has a relative efficiency of 1, the ORF 14558 is less than 1/10 of the effectiveness of the ORF 16600.
Suppression of cyclophosphodiesterase cardiovascular cyclic AMP LC50 shown in the table. H.
1344246
8 Continuation of table 1
+ 11 + 19 + 20- + 19 + 31 + 16 +25 + 13 + 13 About
-14
-eleven
-sixteen
-35
-23
-four
-40
-6
-6
+8
The data in the table. 3 illustrate
that ORF 16600 is also more effective (4-6 times) as an inhibitor of the cardiovascular activity of phosphodiesterase compared with ORF 14558. Since the suppression of this activity
The enzyme can be a biochemical mechanism to improve the force of contraction of the heart and decrease after the load (arterial blood pressure), these data are combined
with in vivo experiments demonstrate that ORF 16600 has an unexpectedly high cardiotonic activity compared with its isomers.
5,6-Dimethoxy-4-methyl-2 (1H) -quinazolinone (ORF 16600) showed an unexpectedly high activity and efficiency in vivo compared with all other dimethoxyaromatic
positional isomers and has about 10 times higher efficiency than any of its isomers as a positive inotropic agent (increases the strength of contractions).
13А4246
() increase in efficacy. also ns o / sets in vivo, since ORF 16600 was found to be more than five times more effective as an inhibitor of phosphodiesterase cardio activity than 6.7 isomer. Results show that bla-1-gifted by its excellent in vivo and in vitro ORF activity and activity
ORi
about DOS
oshg
-N02
where RI is lower alkyl, hydrogenated with platinum oxide to form 2,3-dialkoxy-6-amy16600, it has excellent cardioto, Q nobenzaldehydeethylene ketal has general fornical properties and is suitable for clinical practice for treating congestive heart failure.
Table 2
Compound
Relative efficiency

one
0.09 (0.05-0.15)
Table H Heart i Vessels
Serde
mules
ORi
g /
Oshg
 «« CHSNG
WITH
NH
ethyl chloride K, is lower alkyl, is reacted with a formate of the Formula
cicC
in the medium of the solvent formed 2, 3-dialkoxy-6-ethoxycarbonylamino-benzaldehyde ethylene ketal of the general formula

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining substituted quinazolinone-2 with the general formula
thirty
Rto
ORi,
 NHC €
about
.five
where R is lower alkyl, is reacted with hydrochloric acid to form 2,3-dialkoxy-6-ethoxycarbonylaminobenzaldehyde of the general formula
where R is lower alkyl, characterized in that the compound of the general formula
ORi
N0-2.
where R is lower alkyl, is reacted with ethylene glycol in the presence of p-toluene sulfonic acid in a solvent at the boiling point of the reaction mass, resulting in 2,3-dialkoxy-6-nitrobonzaldehydeethylene ethylene unit. th formulas
ORi
11ns
: 0
where R is lower alkyl, is reacted with ammonia 50 in the medium of a solvent that forms a quinazolinone of the general formula
. Where R, is lower alkyl, is reacted with alkyl. 111344246 2
with magnesium bromide in a solvent, where R is lower alkyl, the quinazolinone formed of the general form is reacted with potassium permanganate in a solvent.
ORi RI
RiOv sOiNH
n
Compiled by G.Zhukova Editor N.Gunko Tehred I.Popovich Proofreader L.Patay
 4839/58 Circulation 371 Subscription
VNIIPI USSR State Committee for Inventions and Discoveries 113035, Moscow, Zh-35, Raushsk nab, d. 4/5
Production and printing company, Uzhgorod, st. Project, 4

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1344246A3|1987-10-07|Method of producing substituted quinazolinons-2

---

US5401753A|1995-03-28|Substituted n-heteroaryl-1, 2-diaminocyclobutene-3, 3-diones

---

FI66372B|1984-06-29|FRAMEWORK FOR THE PHARMACOLOGICAL PROCESSING OF THE PHARMACOLOGICAL NETWORK I 5-ELLER 6-STATIONARY MEDIUM PYRIDAZINONRING SUBSTITUERADE BESIMIDAZOLER

---

JPH05208957A|1993-08-20|New r-and s-carbazole derivatives

---

US5506252A|1996-04-09|Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones

---

WO1995003279A1|1995-02-02|Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring

---

IE54473B1|1989-10-25|Imidazolylphenyl-tetrahydropyridazines, processes for their preparation and pharmaceutical preparations containing them

---

KR920007557B1|1992-09-07|Biologically active nitrogen heterocycles

---

JPH10182583A|1998-07-07|New hydroxamic acid derivative

---

EP0125749B1|1988-10-05|Imidazolyl-pyridazinones

---

EP0156331B1|1989-05-31|Benzofuran derivatives, processes for preparing the same and antihypertensive agents containing the same

---

US4134991A|1979-01-16|Derivatives of 2-|-acetic acid

---

US4902698A|1990-02-20|Benzenesulphonamidopyridyl compounds which are useful as thromboxane A.sub.2

---

US4908378A|1990-03-13|Benzopyran derivatives and antihypertensive use thereof

---

SK14698A3|1998-10-07|Benzenesulphonamide derivatives, preparation thereof and therapeutical uses thereof

---

DE2854475A1|1980-07-03|NEW 3,4-DIAZA-BICYCLO ANGLE CLAMP ON 4.1.0 ANGLE CLAMP FOR HEPTING- | - ONE- |, METHOD FOR THE PRODUCTION THEREOF AND THESE COMPOUNDS THERAPEUTIC AGENTS

---

US4912135A|1990-03-27|Amide compounds

---

EP0538477B1|2002-10-16|Novel cyclic aminophenylacetic acid derivative, production thereof, and immune response modulator containing the same as active ingredient

---

SU1255052A3|1986-08-30|Method of producing substituted imidazopyrimidines,-pyrazines,or -triazines or salts thereof,which are acceptable in pharmacology

---

DE3209159A1|1983-09-15|NEW 6-ARYL-4,5-DIHYDRO-3 | -PYRIDAZINONE, METHOD FOR THE PRODUCTION THEREOF, THERAPEUTICAL AGENTS CONTAINING THESE COMPOUNDS AND THE USE THEREOF

---

HU196381B|1988-11-28|Process for preparing 8-halogen-5,6-dialkoxy-quinazolin-2,4-dione derivatives

---

US5482942A|1996-01-09|chromene, indene, and dihydronaphthalenone derivatives as smooth muscle relaxants

---

US4372956A|1983-02-08|5, 10-Dihydroimidazo[2,1-b]quinazolines and pharmaceutical compositions containing them

---

JPH07242670A|1995-09-19|Pyrrolo|pyrazolo|pyrimidine derivative and circulatory disease-treating agent using the same

---

US4745118A|1988-05-17|Substituted quinazoline-3-oxides providing pharmacological activity

同族专利:

---

公开号 | 公开日

---

FI833523A0|1983-09-29|

---

AU1979483A|1984-04-05|

---

DK449183A|1984-03-31|

---

SU1407398A3|1988-06-30|

---

EP0220786A2|1987-05-06|

---

GB2163426A|1986-02-26|

---

IE832307L|1984-03-30|

---

DK449183D0|1983-09-29|

---

DK159311C|1991-03-11|

---

AU563958B2|1987-07-30|

---

EP0220786B1|1990-11-22|

---

DK159311B|1990-10-01|

---

GR79366B|1984-10-22|

---

GB8326030D0|1983-11-02|

---

EP0107398A1|1984-05-02|

---

EP0220786A3|1988-02-24|

---

PT77422A|1983-10-01|

---

PT77422B|1986-09-10|

---

IE56413B1|1991-07-31|

---

HK98787A|1987-12-31|

---

US4490374A|1984-12-25|

---

JPS60204770A|1985-10-16|

---

GB2127823A|1984-04-18|

---

FI833523A|1984-03-31|

---

JPS5982374A|1984-05-12|

---

GB2163426B|1987-01-07|

---

HK98887A|1987-12-31|

---

CA1215712A|1986-12-23|

---

GB8519309D0|1985-09-04|

---

ZA837302B|1985-05-29|

---

EP0107398B1|1988-06-08|

---

GB2127823B|1987-01-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB1280551A|1968-07-01|1972-07-05|Sandoz Ltd|Quinazoline derivatives|

---

US3859237A|1970-04-20|1975-01-07|Sumitomo Chemical Co|Quinazoline derivatives|

---

DE2118315C3|1970-04-20|1975-04-03|Sumitomo Chemical Co., Ltd., Osaka |2- -quinazolinone derivatives, processes for their preparation and pharmaceuticals containing these compounds|

---

US3950526A|1970-04-20|1976-04-13|Sumitomo Chemical Company, Limited|Quinazoline derivatives in pharmaceutical compositions for treating pain and inflammation|

---

SE392616B|1971-06-29|1977-04-04|Sumitomo Chemical Co|PROCEDURE FOR THE PREPARATION OF KINAZOLINONE COMPOUNDS|

---

JPS5013271B2|1971-10-04|1975-05-19|

---

JPS4948957B2|1971-10-26|1974-12-24|

---

JPS4887012A|1972-02-21|1973-11-16|

---

JPS555506B2|1972-09-07|1980-02-07|

---

JPS5217842A|1975-07-31|1977-02-10|Canon Inc|Device for fabricating sound hologram|

---

ZA796623B|1978-12-07|1981-07-29|Ortho Pharma Corp|Substituted pyrrolo quinazolines|

---

AU533427B2|1978-12-07|1983-11-24|Ortho Pharmaceutical Corporation|Substituted 2 quinazolinones|

---

GB2039895B|1978-12-07|1983-03-02|Ortho Pharma Corp|4-substituted-2quinazolinones|

---

JP5217842B2|2008-09-25|2013-06-19|株式会社リコー|Recording paper feeding apparatus and image forming apparatus|US4617392A|1983-09-29|1986-10-14|Ortho Pharmaceutical Corporation|4-alkyl-5,6-methylenedioxy-2-1[H]-quinazolinones useful as cardiotonic agents|

---

US4656267A|1983-09-29|1987-04-07|Ortho Pharmaceutical Corporation|Substituted 2-quinazolinone-1-alkanoic acids and esters|

---

US4556739A|1983-09-29|1985-12-03|Ortho Pharmaceutical Corporation|3,4-Dialkoxy-2-alkylcarbonyl analino compounds|

---

US4731480A|1985-07-29|1988-03-15|Ortho Pharmaceutical Corporation|Process for preparing 2-acyl-3,4-dialkoxyanilines|

---

KR900003529B1|1985-07-29|1990-05-21|오르토 파마슈티컬 코포레이션|Process for preparing 2-acyl-3,4-di'alkoxyanilines|

---

GB8524663D0|1985-10-07|1985-11-13|Fujisawa Pharmaceutical Co|Quinazoline derivatives|

---

US4975428A|1988-05-31|1990-12-04|Iolab Corporation|Treatment of glaucoma using phosphodiesterase inhibitors|

---

AU2436792A|1991-08-16|1993-03-16|Merck & Co., Inc.|Quinazoline derivatives as inhibitors of hiv reverse transcriptase|

---

IL102764D0|1991-08-16|1993-01-31|Merck & Co Inc|Quinazoline derivatives,and pharmaceutical compositions containing them|

---

US6749598B1|1999-01-11|2004-06-15|Flowmedica, Inc.|Apparatus and methods for treating congestive heart disease|

---

US7329236B2|1999-01-11|2008-02-12|Flowmedica, Inc.|Intra-aortic renal drug delivery catheter|

---

US7780628B1|1999-01-11|2010-08-24|Angiodynamics, Inc.|Apparatus and methods for treating congestive heart disease|

---

AU1462101A|1999-11-22|2001-06-04|Warner-Lambert Company|Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes|

---

US6982260B1|1999-11-22|2006-01-03|Warner-Lambert Company|Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes|

---

US7481803B2|2000-11-28|2009-01-27|Flowmedica, Inc.|Intra-aortic renal drug delivery catheter|

---

US7122019B1|2000-11-28|2006-10-17|Flowmedica Inc.|Intra-aortic renal drug delivery catheter|

---

US7063679B2|2002-09-20|2006-06-20|Flowmedica, Inc.|Intra-aortic renal delivery catheter|

---

JP2006526464A|2003-06-05|2006-11-24|フローメディカ，インコーポレイテッド|System and method for performing bilateral intervention or diagnosis in a branched body lumen|

---

AU2003276903A1|2002-09-20|2004-05-04|Flowmedica, Inc.|Method and apparatus for selective material delivery via an intra-renal catheter|

---

WO2004030718A2|2002-09-20|2004-04-15|Flowmedica, Inc.|Method and apparatus for intra aortic substance delivery to a branch vessel|

---

AU2003300779A1|2002-09-20|2004-05-04|Flowmedica, Inc.|Catheter system for renal therapy|

---

US7993325B2|2002-09-20|2011-08-09|Angio Dynamics, Inc.|Renal infusion systems and methods|

---

US20050197624A1|2004-03-04|2005-09-08|Flowmedica, Inc.|Sheath for use in peripheral interventions|

---

US7585836B2|2004-05-14|2009-09-08|Goodson Iv Harry Burt|Bi-lateral local renal delivery for treating congestive heart failure and for BNP therapy|

---

US7771401B2|2006-06-08|2010-08-10|Angiodynamics, Inc.|Selective renal cannulation and infusion systems and methods|

---

KR101691954B1|2016-04-26|2017-01-02|고려대학교 산학협력단|Novel N-acylurea Derivatives and Composition for Prevention or Treatment of Cardiovascular Disorders Comprising the Same|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/430,552|US4490374A|1982-09-30|1982-09-30|5,6-Dialkoxy-3,4-optionally substituted-2quinazolinones, composition and method of use|

---

JP59058527A|JPS60204770A|1982-09-30|1984-03-28|Dihydroxy-2quinazoline-1-alkanoic acids|

---